Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think!opens in new tab/window

Elsevier
Publish with us

Alyson Kelvin

AK

Alyson Kelvin

University of Saskatchewan, Canada

Alyson Kelvin, PhD. Dr. Kelvinopens in new tab/window is a Scientist II at the Vaccine and Infectious Disease Organization (VIDO)opens in new tab/window, Saskatoon, Canada. She completed her HBSc at Western University (London, Canada, 2003) and her PhD at Queen’s University (Belfast, Northern Ireland, 2007). Dr. Kelvin’s expertise is in the fields of virology and vaccinology specifically focusing on the development of broadly protective vaccines for emerging viruses. She has researched several high-profile emerging viruses including the 2009 H1N1 pandemic influenza virus, avian H5N1 influenza virus, Mpox virus, SARS-CoV, and SARS-CoV-2. She is a member of expert panels for the control of emerging viruses including the Public Health Agency of Canada’s (PHAC) Avian Influenza Expert Panel. Dr. Kelvin has been recognized with a CEPI-CIHR Leadership Award in Vaccine Research as well as the Canadian Society for Virology Early Career Award of Excellence.